Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...

Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...

Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...

Johnson & Johnson offers safer payouts and stronger growth. Discover why JNJ stock is the better dividend option compared to ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) and keeping the price ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

Richard Wright, 46, lost his mum Maureen at the age of 13 to ovarian cancer but has now joined a group lawsuit against ...

Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.

Johnson & Johnson (J&J) announced that it has agreed to terms on a global licensing agreement with Kaken Pharmaceutical for the global development, manufacturing, and commercialization of Kaken’s ...

Apalutamide is under clinical development by Johnson & Johnson and currently in Phase II for Prostate Cancer. According to GlobalData, Phase II drugs for Prostate Cancer have a 23% phase transition ...

JNJ-2056 is under clinical development by Johnson & Johnson Innovative Medicine and currently in Phase II for Tauopathies.

Exclusive: Jane Campbell is one of thousands of women in the UK planning legal action against one of the world’s largest ...